Spherix Global Insights

Can Pharma Companies Expand the Current Ankylosing Spondylitis (AS) Market with a New Indication

August 1, 2017 (STL.News) According to the surveyed physicians, biologic agents are prescribed in just over half of the AS patients under their management but in a significantly lower proportion of their nr-axSpA patients.  The specific biologic brands prescribed, however, do not differ significantly in terms of share between AS and nr-axSpA, with AbbVie’s Humira … Continue reading Can Pharma Companies Expand the Current Ankylosing Spondylitis (AS) Market with a New Indication